METHODS OF TREATMENT USING TITANIUM AND SILVER NANOPARTICLES MADE WITH AN INTRACELLULAR EXTRACT OF FOMES FOMENTARIOUS
20220331354 · 2022-10-20
Assignee
Inventors
Cpc classification
B82Y5/00
PERFORMING OPERATIONS; TRANSPORTING
A61P31/00
HUMAN NECESSITIES
B82Y30/00
PERFORMING OPERATIONS; TRANSPORTING
B82Y40/00
PERFORMING OPERATIONS; TRANSPORTING
International classification
Abstract
Silver and titanium oxide nanoparticles produced with Fomes fomentarius or Fomitopsis pinicola aqueous extracts and methods for treating bacterial infections or cancer using them.
Claims
1. Fomes fomentarius-TiO.sub.2 nanoparticles that comprise a rutile phase or Fomes fomentarius-Ag nanoparticles comprising a fcc structure; wherein said Fomes fomentarius-TiO.sub.2 nanoparticles exhibit by Fourier transform infrared (FT-IR) spectroscopy absorption peaks between 766-1630 cm.sup.−1 corresponding to Ti—O, aliphatic C—N, and aromatic C═N bands; and wherein said Fomes fomentarius-Ag nanoparticles exhibit by Fourier transform infrared (FT-IR) spectroscopy a broad adsorption peak at about 3290 cm.sup.−1 corresponding to hydroxyl (—OH) and N—H stretching of primary amines.
2. A composition comprising a pharmaceutically acceptable carrier or excipient and at least one nanoparticle of claim 1.
3. A composition comprising a soap, surfactant, bleach, hydrogen peroxide, or other cleaner and at least one nanoparticle of claim 1.
4. A method for making Fomes fomentarius-Ag nanoparticles or Fomes fomentarius-TiO.sub.2 nanoparticles of claim 1 comprising: combining an aqueous extract of Fomes fomentarius with silver nitrate under conditions suitable for producing Fomes fomentarius-Ag nanoparticles; or combining an aqueous extract of Fomes fomentarius with titanium isopropoxide under conditions suitable for producing Fomes fomentarius-TiO.sub.2 nanoparticles.
5. A method for treating a microbial infection or cancer, comprising: administering to a subject in need thereof at least one of Fomes fomentarius-TiO.sub.2 nanoparticles or Fomes fomentarius-Ag nanoparticles of claim 1 in an amount sufficient to inhibit growth or viability of a microorganism or proliferation or viability of the cancer.
6. The method of claim 5, wherein Fomes fomentarius-Ag nanoparticles having an average diameter ranging from 10 to 30 nm are administered.
7. The method of claim 5, wherein Fomes fomentarius-TiO.sub.2 nanoparticles having an average diameter ranging from 80 to 120 nm are administered.
8. The method of claim 5, wherein the Fomes fomentarius-TiO.sub.2 nanoparticles are made using an aqueous extract of Fomes fomentarius and titanium isopropoxide and the Fomes fomentarius-Ag nanoparticles are made using an aqueous extract of Fomes fomentarius and silver nitrate.
9. The method of claim 5, wherein said subject is in need of treatment of a bacterial infection.
10. The method of claim 5, wherein said subject is in need of treatment for cancer
11. Fomitopsis pinicola-TiO.sub.2 nanoparticles that comprise a rutile phase or Fomitopsis pinicola-Ag nanoparticles comprising a fcc structure; wherein said Fomitopsis pinicola-TiO.sub.2 nanoparticles exhibit by Fourier transform infrared (FT-IR) spectroscopy adsorption at 1000, 1414, and 1644 cm.sup.−1 respectively corresponding to C═N, C—N and (TiO.sub.2, OH and C═O); and wherein said Fomitopsis pinicola-Ag nanoparticles exhibit by Fourier transform infrared (FT-IR) spectroscopy peak absorption of linear aliphatic amines (C—N) at 1000-1040 cm.sup.−1.
12. A composition comprising a pharmaceutically acceptable carrier or excipient and at least one nanoparticle of claim 11.
13. A composition comprising a soap, surfactant, bleach, hydrogen peroxide, or other cleaner and at least one nanoparticle of claim 11.
14. A method for making Fomitopsis pinicola-Ag nanoparticles or Fomitopsis pinicola-TiO.sub.2 nanoparticles of claim 11 comprising: combining an aqueous extract of Fomitopsis pinicola with silver nitrate under conditions suitable for producing Fomitopsis pinicola-Ag nanoparticles; or combining an aqueous extract of Fomitopsis pinicola with titanium isopropoxide under conditions suitable for producing Fomitopsis pinicola-TiO.sub.2 nanoparticles.
15. A method for treating a microbial infection or cancer, comprising: administering to a subject in need thereof at least one of Fomitopsis pinicola-TiO.sub.2 nanoparticles or Fomitopsis pinicola-Ag nanoparticles of claim 11 in an amount sufficient to inhibit growth or viability of a microorganism or proliferation or viability of the cancer.
16. The method of claim 15, wherein Fomitopsis pinicola-Ag nanoparticles having an average diameter ranging from 10 to 30 nm are administered.
17. The method of claim 15, wherein Fomitopsis pinicola-TiO.sub.2 nanoparticles having an average diameter ranging from 80 to 120 nm are administered
18. The method of claim 15, wherein the Fomitopsis pinicola-TiO.sub.2 nanoparticles are made using an aqueous extract of Fomitopsis pinicola and titanium isopropoxide and the Fomitopsis pinicola-Ag nanoparticles are made using an aqueous extract of Fomitopsis pinicola and silver nitrate.
19. The method of claim 15, wherein said subject is in need of treatment of a bacterial infection.
20. The method of claim 15, wherein said subject is in need of treatment for cancer.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0045] A more complete appreciation of the invention and many of the attendant advantages thereof will be readily obtained as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings, wherein:
[0046]
[0047]
[0048]
[0049]
[0050]
[0051]
[0052]
[0053]
[0054]
[0055]
[0056]
[0057]
[0058]
[0059]
[0060]
[0061]
[0062]
[0063]
[0064]
[0065]
[0066]
[0067]
[0068]
[0069]
[0070]
[0071]
[0072]
[0073]
[0074]
[0075]
[0076]
[0077]
[0078]
[0079]
[0080]
[0081]
[0082]
[0083]
[0084]
[0085]
[0086]
[0087]
[0088]
[0089]
[0090]
[0091]
[0092]
[0093]
[0094]
[0095]
[0096]
[0097]
[0098]
[0099]
[0100]
[0101]
[0102]
[0103]
[0104]
[0105]
DETAILED DESCRIPTION OF THE INVENTION
[0106] The present disclosure describes a green, bio-directed process for synthesis of silver nanoparticles (AgNPs) and titanium oxide (TiO.sub.2) nanoparticles from an amalgamation of aqueous extracts of Fomes fomentarius or Fomitopsis pinicola and silver nitrate or titanium (iv) isopropoxide.
[0107] F. fomentarius was identified phenotypically and by 18S ribosomal RNA gene sequencing (Gene accession no: MK635351) and F. pinicola by 18S ribosomal RNA gene sequencing (Gene accession no MK635350).
[0108] Aqueous extracts or aqueous-alcohol (e.g., aqueous methanol or ethanol) extracts may be produced by homogenizing, macerating, sonicating or otherwise disrupting samples of these fungi and suspending the material in water or an aqueous buffer, including but not limited to aqueous methanol or aqueous ethanol. Alcohol content can vary between 0, 10, 20, 30, 40, 50, 60, 70 80, 90 or >90% by volume. In a preferred embodiment, fungal material is dried and powdered prior to extraction. The extract is preferably clarified by removal of solid components, for example, by filtration or centrifugation prior to use. However, in some embodiments, nanoparticles of solid fungal material may be retained in an extract, for example, particles ranging in size <1, 1, 2, 5, 10, 20, 50, 100, 200, 500 or <1,000 nm in diameter or broadest dimension. Preferably the extract is produced and stored at a temperature less than 30, 25, 20, 15, 10, 5 or 0° C.
[0109] Silver and titanium oxide nanoparticles may be produced by amalgamating or contacting an aqueous fungal extract with silver nitrate (or other silver salts) or titanium isopropoxide (or other titanium salts, such as titanium sulfate salts, nitrate salts, chloride salts and oxide salts) for a time and under conditions sufficient to form silver nanoparticles or titanium oxide nanoparticles from the amalgamated mixture of fungal extract of silver nitrate or titanium isopropoxide. The nanoparticles once formed may be separated from the liquid components of the amalgamation and washed and resuspended.
[0110] The biosynthesis of the TiO.sub.2 and AgNPs were studied and characterized by X-ray diffraction (XRD), diffuse reflectance UV-Visible spectroscopy (DR-UV), Fourier transform infrared spectroscopy (FT-IR), scanning electron microscopy (SEM) and transmission electron microscope (TEM).
[0111] The inventors found that nanoparticle size could be controlled by altering the concentration of AgNO.sub.3 or titanium isopropoxide, altering the concentration of the mushroom extracts, altering the length of incubation time of the nanoparticle precursor, and/or decreasing or increasing the pH during incubation. Success was achieved in obtaining NPs of differing sizes and shapes, for example it is possible to produce a TiO.sub.2 nanoparticle having approximately the same 10-20 or 10-30 nm average diameter as the Ag NPs.
[0112] The antibacterial and anticancer activities of the TiO.sub.2 and AgNPs made with F. fomentarius extracts were significant with morphological damage being caused by both, although AgNPs (10-20 nm) were found to have greater effects on bacterial and cancer cells in comparison to TiO.sub.2NPs (100-120 nm in average diameter).
[0113] The antibacterial and anticancer activities of the TiO.sub.2 and AgNPs made with F. pinicola, were significant, however, enhanced antibacterial and anticancer actions were seen with AgNPs (10-30 nm in average diameter).
[0114] TiO.sub.2 and AgNPs synthesized using F. fomentarius and F. pinicola extracts, have numerous biomedical applications in biomedicine due to an effective enzyme combination which permits them to modify different chemical compounds more safely or into less toxic forms as required for ecofriendly and safe biomaterials.
[0115] Modes of administration. The methods of administering the nanoparticles or compositions containing them disclosed herein may comprise administering a silver or titanium oxide nanoparticle composition or composition intravenously, intramuscularly, topically (e.g. on or into a wound or precancerous or cancerous lesion), intradermally, into or over a wound, intramucosally, subcutaneously, sublingually, orally, intravaginally, intracavernously, intraocularly, intranasally, intrarectally, gastrointestinally, intraductally, intrathecally, subdurally, extradurally, intraventricular, intrapulmonary, into an abscess, intra articularly, into a bursa, subpericardially, into an axilla, intrauterine, into the pleural space, intraperitoneally, transmucosally, or transdermally.
[0116] Carriers/Excipients. The term carrier encompasses any excipient, binder, diluent, filler, salt, buffer, solubilizer, lipid, stabilizer, or other material well known in the art for use in pharmaceutical formulations, for example, for intravenous administration a carrier may be sodium chloride 0.9% or mixtures of normal saline with glucose or mannose. The choice of a carrier for use in a composition will depend upon the intended route of administration for the composition. The preparation of pharmaceutically acceptable carriers and formulations containing these materials is described in, e.g., Remington's Pharmaceutical Sciences, 21st Edition, ed. University of the Sciences in Philadelphia, Lippincott, Williams & Wilkins, Philadelphia Pa., 2005, which is incorporated herein by reference in its entirety.
[0117] Formulations for administration. For therapeutic purposes, formulations for parenteral administration can be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. The term parenteral, as used herein, includes intravenous, intravesical, intraperitoneal, subcutaneous, intramuscular, intralesional, intracranial, intrapulmonal, intracardial, intrasternal, and sublingual injections, or infusion techniques.
[0118] Topical administration. Formulations for topical administration to the skin, wounds, burns, or mucous membranes include, for example, ointments, creams, gels and pastes comprising the composition in a pharmaceutical acceptable carrier. The formulation of the composition for topical use includes the preparation of oleaginous or water-soluble ointment bases, as is well known to those in the art. For example, these formulations may include vegetable oils, animal fats, and, for example, semisolid hydrocarbons obtained from petroleum. Particular components used may include white ointment, yellow ointment, cetyl esters wax, oleic acid, olive oil, paraffin, petrolatum, white petrolatum, spermaceti, starch glycerite, white wax, yellow wax, lanolin, anhydrous lanolin and glyceryl monostearate. Various water-soluble ointment bases may also be used, including glycol ethers and derivatives, polyethylene glycols, polyoxyl 40 stearate and polysorbates.
[0119] Oral administration. Solid preparations for oral administration may include a tablet, a pill, a powder, a granule, a capsule, and the like. These solid preparations may be prepared by mixing at least one excipient, such as starch, calcium carbonate, sucrose, lactose, or gelatin, with nanoparticle as disclosed herein. In addition to such a simple excipient, lubricants, such as magnesium stearate and talc, may be used. Liquid preparations containing nanoparticles for oral administration correspond to a suspension, a liquid for internal use, oil, syrup, and the like, and may include several types of excipient, for example, a wetting agent, a sweetener, an aroma, a preservative, and the like, in addition to simple diluents that are frequently used, such as water and liquid paraffin.
[0120] Parenteral administration. Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions containing nanoparticles can be formulated according to the known art using suitable dispersing or wetting ingredients and suspending ingredients. The sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids, such as oleic acid, find use in the preparation of injectables. Dimethyl acetamide, surfactants including ionic and non-ionic detergents, polyethylene glycols can be used. Mixtures of solvents and wetting ingredients such as those discussed above are also useful.
[0121] Respiratory system administration. Administration to the respiratory system may be accomplished using a drug delivery device such as a nebulizer to administer a nanoparticle composition as disclosed herein, in an inhalable form. Nebulizers include soft mist inhalers, jet nebulizers, ultrasonic wave nebulizers, and nebulizers using vibrating mesh technology. A metered-dosage inhaler is another drug delivery device that delivers a selected or metered amount of a medication, such as the nanoparticle compositions disclosed herein. Typically, this device produces and releases an aerosol of micrometer-sized particles that are inhaled.
[0122] Thus, preferably, the nanoparticles are sized so as to provide a uniform dosage or so they are absorbed in a particular part of the respiratory system. In some cases, the particles may be a dry powder in others as a mist or in a semiliquid form. Metered-dose inhalers and their various components, propellants, excipients and other elements are described by and incorporated by reference to hypertext transfer protocol secure://en.wikipedia.org/wiki/Metered-dose_inhaler. An inhalable composition may be formulated in the form of a hydrofluoroalkane inhaler or HFA (metered dose inhaler or MDI), dry powder inhaler (DPI), or as a nebulizer solution.
[0123] Dose. The dose of a nanoparticle composition as disclosed herein with respect to the human or animal body may vary depending on patient's age, body weight, and gender, the form of administration, state of health, and severity of disease. The dose may be generally 0.01-100 mg/kg/day, preferably 0.1-20 mg/kg/day, and more preferably 5-10 mg/kg/day. The composition may also be divisionally administered at predetermined intervals according to the determination of a doctor or pharmacist.
[0124] Antibiotics which may be further incorporated into a nanoparticle composition or coadminstered therewith, include but are not limited to the following. Penicillins for example, phenoxymethylpenicillin, flucloxacillin and amoxicillin; Cephalosporins for example, cefaclor, cefadroxil and cefalexin; Tetracyclines for example, tetracycline, doxycycline and lymecycline. Aminoglycosides—for example, gentamicin and tobramycin; and Macrolides—for example, erythromycin, azithromycin and clarithromycin. One or more antibiotic may be administered in combination with an Ag or TiO.sub.2nanoparticle as disclosed herein.
[0125] Anti-cancer drugs. The Ag and TiO.sub.2 fungal nanoparticles disclosed herein may be administered with cancer chemotherapeutics including but not limited to alkylating agents, antimetabolites, topoisomerase inhibitors, antibiotics, mitotic inhibitors, and protein kinase inhibitors. Specific anti-cancer drugs include but are not limited to Avastin (Bevacizumab), Bevacizumab, Camptosar (Irinotecan Hydrochloride), Capecitabine, Cetuximab, Cyramza (Ramucirumab), Eloxatin (Oxaliplatin), Erbitux (Cetuximab), 5-FU (Fluorouracil Injection), Fluorouracil Injection, Ipilimumab, Irinotecan Hydrochloride, Keytruda (Pembrolizumab), Leucovorin Calcium, Lonsurf (Trifluridine and Tipiracil Hydrochloride), Mvasi (Bevacizumab), Nivolumab, Opdivo (Nivolumab), Oxaliplatin, Panitumumab, Pembrolizumab, Ramucirumab, Regorafenib, Stivarga (Regorafenib), Trifluridine and Tipiracil Hydrochloride, Vectibix (Panitumumab), Xeloda (Capecitabine), Yervoy (Ipilimumab), Zaltrap (Ziv-Aflibercept), Zirabev (Bevacizumab), and Ziv-Aflibercept.
[0126] Cosmetics. Medical or cosmetic amorphous formulations in the form of creams, lotions, ointments, gels, shampoos, conditioners, moisturizers, or antiperspirants can be readily prepared by blending in the antimicrobial AgNPs or TiO.sub.2 NPs as disclosed herein. Preparations such as the serums, creams, lotions, gels, shampoos, conditioners, emulsions, salves or ointments, and antiperspirants are known to those ordinarily skilled in the art.
[0127] Other compositions. The nanoparticle compositions as disclosed herein can be used in other compositions where an antimicrobial environment is desired or where a reduction in microbial growth, or a reduction in odor would be useful. For example, the silver or TiO.sub.2 nanoparticles compositions may be added to cleaners, laundry or dishwashing detergents, paints, cosmetics, on wound dressings to control of odor from wound exudates, in dental compositions, in products used in bowel or vascular surgery, oral hygiene products, bathroom products, textile products, coatings, natural or synthetic polymers adhesives, paint products, polymer films, paper, leather, rubber and plastic articles. Unfinished and finished articles such as yarn or bolts of cloth may also be rendered antimicrobial.
EXAMPLE 1
Nanoparticles Made with Fomes fomentarius
[0128] Collection, Phenotypic and Genotypic Studies of Fomes fomentarius. For the collection of sporocarps, a standard method was followed, see Krueger, D. Monographic Studies in the Genus Polyporus (Basidiomycotina). Incorporated by reference and available online: hypertext transfer protocolsecure://trace.tennessee.edu/utk_graddiss/2135/ (accessed on 6 Apr. 2021). Photographs were taken by a Nikon D5300 DSLR Camera (Nikon, Tokyo, Japan) with a zoom lens of 18-140 VR (data of sampling in supplementary file). Passport data and the microhabitat characteristics of collected samples has Biomolecules 2020, 10, 622 3 of 15 been recorded in the field book. Samples were properly labeled, given a voucher number and carried to the laboratory for detailed morphometric examination. Collected specimens were identified by keen observation of structures like pileus, stipe, their shape, structure, gill attachment, etc., using standard keys (e.g., Mycokey, Index fungoram etc.) field guides and manuals.
[0129] The samples were dried and deposited at the herbarium of the Centre for Biodiversity and Taxonomy, University of Kashmir, J&K, India. Microscopic features and measurements were made from slides that were prepared and stained with lactophenol cotton Blue, 2% KOH and Melzer's reagent. For examination, the spores were tapped off the razor blade onto a clean slide and a drop of KOH or Melzer's reagent was added. Observation and photographs were captured at magnification between ×40 to ×100 using a Nikon Eclipse 80i microscope and phase contrast illumination (Nikon, Tokyo, Japan).
[0130] Isolation and PCR DNA extraction was done using the manual CTAB method (cetyl trimethylammonium bromide); Mohanta, Y.; et al.,. Silver nanoparticles synthesized using wild mushroom show potential antimicrobial activities against food borne pathogens. M
[0131] The extracted DNA was dissolved and preserved in TE (Tris-EDTA) buffer. The amplification was carried out for internal transcribed spacer (ITS) regions using the ITS1 and ITS4 in a PCR System Thermocycler Applied Biosystems with following parameters-10 min of initial denaturation at 95° C., 35 cycles at 95° C. for 1 min, 54° C. for 30 s and 72° C. for 2 min, followed by extension at 72° C. for 10 min. The purification of amplified products was done and sequenced with the same primers.
[0132] The DNA sequences were submitted to GeneBank and analyzed for homology using BLAST on NCBI (Table 1); Felsenstein, J. PHYLIP (Phylogeny Inference Package), Version 3.57 c. Available online: hypertext transfer protocol://www.dbbm.fiocruz.br/molbiol/main.html (accessed on 6 Apr. 2021).
[0133] Sequence and Phylogeny Analysis. Wild mushroom was identified by ribosomal gene analysis. The small subunit sequences were aligned with additional sequences downloaded from NCBI GenBank (hypertext transfer protocol://ncbi.nim.nih.gov) using BioEdit Sequence Alignment Editor (version 7.2.5). The sequence alignments and phylogenetic analysis were performed using MEGA 10 software (Tamura et al., 2011). Phylogeny was studied on ITS -18S rRNA genes by maximum likelihood method. Initial alignment was done using Clustal W software for maximum alignment and minimum gaps. The tree was generated by using the program DNADIST and NEIGHBOR from PHYLIP 3.69, Felsenstein, J. et al., supra.
[0134] Biosynthesis of TiO.sub.2 and AgNPs Using Fomes Fomentarius. The synthesis of TiO.sub.2 and AgNPs was conducted using the extract of F. fomentarius by adopting a green synthesis method; see Mohanta, Y.; et al., Silver nanoparticles synthesized using wild mushroom show potential antimicrobial activities against food borne pathogens. M
[0135] The F. fomentarius sample was dried to obtain powder (10 g), which was further mixed with 100 mL of millipore water and sonicated for 25-30 min. The mixture was further centrifuged at 4000 rpm to obtain the clarified solution. Subsequently, solution was filtered and stored at 4° C. A total of 10 mL of filtrate was mixed with 1 mM AgNO.sub.3 (100 mL) and put at room temperature on a shaker for agitation under observation, until the appearance of color change (10 min). A similar procedure was followed for TiO.sub.2NPs, where 100 mL of 1 mM Titanium (IV) isopropoxide was used as a source solution. The mechanism involved in the production of antimicrobial and anti-cancer NPs using F. fomentarious mushroom extract is unclear.
[0136] Characterization of Biosynthesized TiO.sub.2 and AgNPs. The crystalline phase of the TiO.sub.2 and AgNPs was measured using a benchtop X-ray powder diffractometer MiniFlex 600 (Rigaku, Shibuya, Tokyo, Japan). The sample was measured in 2 theta range 5-80° , with step size of 0.02° and scan rate of 1°/min.
[0137] The coordination environment of TiO.sub.2 and AgNPs were analyzed using diffuse reflectance UV-Visible spectroscopy (V-750, JASCO). The sample for diffuse reflectance was prepared by dispersing the sample in a spherical disc with an integrated sphere (60 mm dia, ISV-922). After pressing, the sample with 0.5 mm thickness was scanned between wavelength range 200-870 nm.
[0138] The TiO.sub.2 and AgNPs functional groups were analyzed using Fourier transform infrared spectroscopy equipped with attenuated total reflectance (ATR) (Perkin Elmer, Arcata, Calif., USA).
[0139] The surface morphology, distribution and features of TiO.sub.2 and AgNPs were studied using scanning electron microscopy (SEM) (Inspect S50) and transmission electron microscope (TEM) (Morgagni 268).
[0140] For TEM analysis, samples were prepared by dispersing in ethanol followed by shaking in an ultrasonicator for 20 min, and then a suspended drop was dried at room temperature on the carbon-coated copper grid; see Rehman, S.; et al., Isolation and characterization of a novel thermophile; Bacillus haynesii, applied for the green synthesis of ZnO nanoparticles. A
[0141] Antibacterial Activity of Biosynthesized NPs. Common pathogenic bacteria Escherichia coli (E. coli ATCC35218) and Staphylococcus aureus (S. aureus ATCC29213) were used for the antibacterial activity of synthesized TiO.sub.2 and AgNPs by agar well diffusion. The bacterial strains were maintained on nutrient agar media (NA).
[0142] In preparation for the antibacterial study, a homogeneous water suspension of the NPs was prepared by sonication for 15-20 min at 30° C. Test organisms grown at 37° C. for 18 h in Mueller Hinton (MHB) were adjusted to the cell density of 10.sup.6 CFU/mL. A total of 100 μL of adjusted inoculum of each bacterial strain was inoculated on the MHA plates. After 20-30 min, the dried plates were punched for wells using the sterile borer. A total of 50 μL of TiO.sub.2NP and AgNP (100 μg/mL) suspension was placed into the wells. Sterile water was used as a negative control. This was followed by the incubation at 37° C. for 24 h. The activity of the synthesized NPs was evaluated by measuring the zone of inhibition zone around the wells in millimeters (mm); see Rehman, S.; et al., supra, incorporated by reference.
[0143] Topological Changes in Treated Bacteria by SEM. Additionally, the treated E. coli and S. aureus were studied by SEM for the morphological and physiological alteration caused by NPs. Precisely, adjusted bacterial cells were treated with 100 μg/mL of TiO.sub.2 and AgNPs and further incubated at 37° C. for overnight. Later, the incubated mixture was centrifuged at 12,000 rpm for 10 min for treated and untreated cells. The harvested cells were thrice washed using PBS and primarily fixed with 2.5% glutaraldehyde for 4 h followed by fixation with 1% osmium tetroxide for 2 h. Cells were washed multiple times and further dehydrated by varying concentrations of ethanol (50%, 70%, 90%, 100%). The cells were placed onto the aluminum stubs and dried using a desecrator. Finally, gold coating was done and cells were examined by SEM at an accelerating voltage of 20 kV; Rehman, S.; et al., Antibacterial and Antifungal Activity of Novel Synthesized Neodymium-Substituted Cobalt Ferrite Nanoparticles for Biomedical Application. P
[0144] Cytotoxic Activity: Cell Culture & Treatments. Human colorectal carcinoma cells (HCT-116) were used for the study. DMEM medium was used, which was supplemented with 10% fetal bovine serum (FBS); (10%) L-glutamine; 10% selenium chloride; 120 μg/mL and streptomycin; and 120 Unit/mL penicillin in a 5% CO2 incubator (Thermo Scientific Heracell-150, Langenselbold Germany) at a temperature of 37° C. The cells with more than 70-80% confluency were used for the TiO.sub.2 and AgNPs treatments. The treatment of HCT-116 cells was carried out with different concentrations of NPs ranging from 0.5 to 8.0 μg/mL. The cells were analyzed after a time span of 48 h. The experiment was carried out in triplicate for statistical analysis; see Khan, F.; et al., FMSP-nanoparticles induced cell death on human breast adenocarcinoma cell line (MCF-7 Cells): Morphometric analysis. B
[0145] Cancer Cell Morphology. The cell morphology of untreated and treated HCT-116 cells was examined post-48 h under an inverted microscope (TS100E-Eclipse, Nikon, Tokya, Japan) and compared under 200× magnification.
[0146] Cytotoxicity by MTT Assay. The cells with confluency of 70-80% in 96-well cell culture plates were subjected to MTT assay. After 48 h, MTT (5 mg/mL) was added in all the wells and kept for 4 h. Later, DMSO was added and the plate was read in an ELISA Plate Reader 570 nm wavelength (Biotek Instruments, Winooski, Vt., USA).
[0147] The (%) percentage of cell viability was calculated as per given formula: Cell Viabilty %=(A/B)×100 where A is optical density of nanoparticles, and B be is optical density of controls.
[0148] Nuclear Staining by DAPI. The cells were stained with DAPI staining to study the effect of TiO.sub.2NPs and AgNPs on the cell nucleus. After 48 h, the treated and untreated HCT-116 cells were immersed in ice-cold (4%) paraformaldehyde. Later, the cells were added with Triton X-100 and prepared in PBS for 5 min to premetallize the cell membrane. The cells were stained using DAPI (5 μg/mL) in PBS, prepared in dark. Washing with Triton X-100 was done, followed by examining the nuclear morphology under confocal scanning microscope (Zeiss, Jena, Germany) equipped with a digital camera; See Anthony, K. J. P.; et al. Synthesis of silver nanoparticles using pine mushroom extract: A potential antimicrobial agent against E. coli and B. subtilis. J. I
[0149] Phenotypic and Genotypic Work with F. fomentarius. Whether extracts of F. fomentarius collected from an angiosperm host in the natural forest of Kashmir valley, India extracts could be employed for the synthesis of TiO.sub.2 and AgNPs was evaluated. The basidiomes of F. fomentarius are perennial, leathery and hoof-shaped. The above surface is smooth and zoned, having a thick crust, and the lower surface is pale brown and concave in shape (
[0150] The ITS1-ITS4 sequences of F. fomentarius were deposited in the NCBI Gene Bank under accession number MK635351. The phylogenetic relationships with related strains are shown in Table 1. The term Fomes fomentarius as used herein describes the strain deposited under MK635351 as well as related strains, such as those described in Table 1 or those having a maximum identity of at least 99.5, 99.6, 99.7%, preferably at least 99.8, 99.9 or 100%, and/or a maximum coverage of at least 98, 99 or 100%.
TABLE-US-00001 TABLE 1 Gene Bank accession numbers and top BLAST match sequences of the mushroom isolates along with maximum identify and query coverage. BLAST Match Sequence Accession Maximum Number Reference Accession Number Coverage Identity MK635351 JX126894.1 Fomes fomentarius 100% 100% KU1391991.1 Fomes fomentarius 100% 100% MK9101131 Fomes fomentarius 100% 99.82% KU863082.1 Fomes fomentarius 100% 99.82% KX065943.1 Fomes fomentarius 100% 99.82%
[0151] Characterization of TiO.sub.2 and AgNPs.
[0152] In the case of AgNPs, clear diffraction lines corresponding to (111), (200) and (220) planes were observed, indicating the presence of face-centered cubic (fcc) crystals. The presence of an additional peak at a 2-theta value of about 51.2 and 52.3 and additional less indexed peaks can be ascribed due to AgNO.sub.3 compounds present in the extract.
[0153] In the case of TiO.sub.2NPs, the formation of crystalline TiO.sub.2was observed with sharp peaks corresponding to the rutile phase. Diffuse reflectance UV-visible spectra were recorded to study the coordination site of titanium oxide and AgNPs in the extract.
[0154] In the case of TiO.sub.2, the band at 220 nm showed the presence of isolated Ti (IV) species, while the octahedral Ti species was found at about 300 nm. In line with XRD analysis, the sample TiO.sub.2showed the presence of a rutile (titania) phase at about 410 nm and expanded to show the presence of agglomeration among TiO.sub.2 nanoparticles with broad absorption extending up to 700 nm.
[0155]
[0156] A reduction in peak intensity and peak position compared to the extract indicates an effective nanoparticle formation.
[0157] In the case of the F. fomentarius mushroom extract, generally an intense peak appears corresponding to the presence of an amino and hydroxyl functional group.
[0158] The AgNPs exhibited a broad peak at about 3290 cm.sup.−1 corresponding to hydroxyl (—OH) and N—H stretching of primary amines (
[0159] A methylene CH stretching peak was observed at 2940 cm.sup.−1. The presence of an asymmetrical C—O stretching peak was observed at 1655 cm.sup.−1.
[0160] The presence of aromatic and aliphatic amines (C—N) was clearly seen with an intense absorption peak at about 1406 and 1000 cm−1.
[0161] The TiO.sub.2NPs had comparatively less intense peak absorption values which were observed between 3000-3680 cm.sup.−1 corresponding to —C—H symmetric stretching (2956 cm.sup.−1) and the hydroxyl group of TiO.sub.2 (3420 cm.sup.−1).
[0162] The presence of a hydroxyl band Ti—OH was clearly observed at 1630 cm.sup.−1.
[0163] Further, the presence of TiO.sub.2NPs was confirmed with absorption peaks between 766-1630 cm.sup.−1, corresponding to Ti—O, aliphatic C—N, and aromatic C═N bands.
[0164] These readings show the presence of various phytocomponents related to amino, methyl and hydroxyl groups present in the mushroom sample which participate in formation and composition of the silver and titanium oxide NPs.
[0165] As shown above and by the FT-IR spectra, the Ag and TiO.sub.2 nanoparticles contain amino and hydroxyl functional groups as shown by N—H bands of primary amines and hydroxyl (—OH) band. The presence of aromatic and aliphatic amines is shown by aliphatic C—N and aromatic C═N bands.
[0166]
[0167]
[0168] As shown by
[0169]
[0170]
[0171] Antibacterial Activity of Synthesized NPs. The antibacterial activity of TiO.sub.2NPs and AgNPs was evaluated by an Agar well diffusion method using E. coli and S. aureus. As shown by
[0172] E. coli had a clear zone of 15 mm and 22 mm in diameter, against TiO.sub.2NPs and AgNPs, respectively. Whereas S. aureus was observed with 11 and 15 mm of clear zones, against TiO.sub.2NPs and AgNPs, respectively. The obtained results indicated that both the NPs have significant activity against both bacteria, with the elevated activity obtained against E. coli, when treated with AgNPs. While not being bound to a particular explanation or theory, the inventors consider that antimicrobial action may be determined by interaction of the disclosed nanoparticles with a cell, such as a bacterium and that components such as ions, from the nanoparticles are released and can diffuse into a culture medium thus exerting an antimicrobial effect.
[0173] This study of antibacterial activity of TiO.sub.2NPs and AgNPs against the Gram-negative and Gram-positive bacteria showed that NPs could arrest the functioning of the cell. AgNPs were more effective obstructing agent. While not being bound to any particular theory or explanation, the inventors consider that silver ions (Ag.sup.+) get released from AgNPs and interact with the phosphorus moieties in bacterial DNA, leading to inactivation of bacterial replication and growth.
[0174] Topological changes caused by the synthesized NPs in E. coli and S. aureus were further evaluated by SEM. The untreated (control) E. coli cells appeared to be rod-shaped, having a consistent and intact cell surface (
[0175] The E. coli cells treated with TiO.sub.2 NPs showed mild alteration, whereas E. coli cells were severely damaged by AgNPs. While not being bound to a particular explanation, the inventors consider that this was attributable to pit formation and distortion of cellular wall and membrane, reflecting the loss of the cellular integrity, and leading to bacterial death.
[0176] On the other hand, the control cells (untreated) S. aureus cells were found in normal coccus shape, with a smooth and continuous cell surface (
[0177] Anticancer Activity of Synthesized NPs. The impact of biosynthesized NPs was examined for microscopic observations and by an MTT cell proliferation assay. Both TiO.sub.2 and AgNPs showed dose-dependent effects on cancer cell survivability as examined by MTT assay.
[0178] The treatment of AgNPs also showed strong cytotoxic effects on cancer cell viability, as a larger majority of the cells were found dead after treatments of lower than 0.5 μg/mL (
[0179] The treatment exhibited significant alterations in cell morphology and the cell nucleus, as revealed by DAPI staining. Clear evidence of condensation and disintegration of the nucleus was seen, with lots of cancer cells found dead during the observation. NP treatment caused significant loss of nuclear staining as compared to control cells (
[0180] The impact of biosynthesized NPs on cancer cells was microscopically examined and examined using an MTT assay. Both TiO.sub.2 and AgNPs produced dose-dependent effects on cancer cell survivability as shown by the MTT assay. Treatment of cancer cells with AgNPs also produced strong cytotoxic effects on cancer cell viability as a larger majority of the cells were found dead after treatments of lower than 0.5 μg/mL (
[0181] Treatment with Fomes fomentarius nanoparticles produced significant alterations in cell morphology and in the cell nucleus as revealed by DAPI staining. Clear evidence of condensation and disintegration of the nucleus was seen and a large proportion of the cancer cells were dead. NP treatment caused significant loss of nuclear staining (
[0182] Treatment with TiO.sub.2 NPs also produced strong cytotoxic effects on cancer cell viability and a large majority of the cells were found dead after treatments of lower than 0.5 μg/mL (
EXAMPLE 2
Nanoparticles Made with Fomitopsis pinicola
[0183] This example describes a bio-directed approach for the formation of titanium oxide and silver nanoparticles (TiO.sub.2 and AgNPs), using a wild mushroom, Fomitopsis pinicola, identified by 18S ribosomal RNA gene sequencing (gene accession no. MK635350) and phenotypic examination.
[0184] NP synthesis was confirmed by X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FT-IR), diffuse reflectance UV-visible spectroscopy (DR-UV), and scanning and transmission electron microscopy (SEM/TEM). Furthermore, the impact of NPs on Escherichia coli and Staphylococcus aureus and a human colon cancer cell line (HCT) were evaluated by MIC/MBC and MTT assays, respectively, along with structural morphogenesis by different microscopy methods. The results showed that Fomitopsis pinicola TiO.sub.2 and AgNPs were significantly active, and that enhanced antibacterial and anticancer action was seen with AgNPs having average diameters ranging from 10-30 nm. Such NPs can be utilized to control and treat infectious diseases and colon cancer and therefore have potential in a range of biomedical applications.
[0185] Collection, phenotypic and genotypic studies of F. pinicola. For the collection of sporocarps, standard method was followed; see D. Krueger, Monographic studies in the genus Polyporus (Basidiomycotina), 2002, incorporated by reference.
[0186] Photographs were taken by Nikon D5300 DSLR Camera with a zoom lens of 18-140 VR. Passport data and the micro-habitat characteristics of collected sample were written in the field book. Each sample was properly labeled, given a voucher number and, carried to a laboratory for detailed morphometric examination. Collected specimens were identified by keen observation of structures like pileus, stipe, their shape, structure, gill attachment, etc., using standard keys (e.g., Mycokey, Index fungorum, etc.) field guides and manuals. The samples were dried and deposited at the herbarium of the Centre for Biodiversity and Taxonomy, University of Kashmir, J&K, India.
[0187] Microscopic features and measurements were made from slides prepared and stained with lactophenol cotton blue, 2% KOH and Melzer's reagent. For spore examination, the spores were tapped off a razor blade onto a clean slide and a drop of KOH or Melzer's reagent was added. Observation and photographs were captured at a magnification between 40× to 100×, using a Nikon Eclipse 80i microscope and phase contrast illumination (Nikon, Tokyo).
[0188] DNA isolation and PCRDNA extraction was done using manual CTAB method (cetyltrimethylammonium bromide); S. Rehman, et al., Comparative studies and identification of camptothecin produced by an endophyte at shake flask and bioreactor, N
[0189] The extracted DNA was dissolved and preserved in TE (Tris—EDTA) buffer. The DNA was amplified for internal transcribed spacer (ITS) regions using the ITS1 and ITS4 in a PCR System Thermocycler Applied Biosystems with following parameters; denaturation for 10 min at 95° C., 35 cycles at 95° C. for 1 min, 54° C. for 30 s and 72° C. for 2 min, followed by extension at 72° C. for 10 min. The purification of amplified products was done and sequenced with the same primers; Rehman, et al., supra, incorporated by reference.
[0190] Sequence and phylogeny analysis. The small subunit sequences were aligned with additional sequences downloaded from NCBI GenBank (hypertext transfer protocol://ncbi.nim.nih.gov) using BioEdit Sequence Alignment Editor (version 7.2.5); P. Dresch, et al., Fungal strain matters: colony growth and bioactivity of the European medicinal polyposes Fomes fomentarius, Fomitopsis pinicola and Piptoporus betulinus, AMB E
[0191] Biosynthesis of TiO.sub.2 and AgNPs using F. pinicola. The synthesis of TiO.sub.2 and AgNPs was conducted using an extract of F. pinicola by adopting a green synthesis method; see Y. Mohanta, et al., Silver nanoparticles synthesized using wild mushroom show potential antimicrobial activities against food borne pathogens, M
[0192] The samples were dried to obtain powder (10 g), which was further mixed with 100 mL of Millipore water and sonicated for 25-30 min. The sonicated mixture was centrifuged at the rpm of4000 to obtain the clarified solution. Subsequently, the solution was filtered and stored at 4° C. 10 mL of filtrate was mixed with 1 mM AgNO.sub.3 (100 mL) and put at room temperature on a shaker for agitation under observation, until the appearance of color change; Mohanta, et al., supra, incorporated by reference.
[0193] A similar procedure was followed for TiO.sub.2 NPs, where100 mL of 1 mM of titanium(IV) isopropoxide was used as source solution (Scheme 1). The mushroom extract to 1 mM AgNO.sub.3 or Ti(OC.sub.3H.sub.7).sub.4 ratio used for the study was 1:10. Finally, the obtained NPs were filtered using Whatman filter paper, washed two times in ethanolic solution and centrifuged (4000 rpm) at 10° C. for 10 min. After drying, the sample was used for further studies.
[0194] Characterization of biosynthesized TiO.sub.2 and AgNPs. The crystalline phase of TiO.sub.2 and AgNPs was measured using benchtop X-ray diffractometer MiniFlex 600 (Rigaku, Japan).
[0195] The coordination environment of TiO.sub.2 and AgNPs were analyzed using diffuse reflectance UV-visible spectroscopy (V-750, JASCO).
[0196] The TiO.sub.2 and AgNPs functional groups were analyzed using Fourier transform infrared spectroscopy (PerkinElmer).
[0197] The surface morphology, distribution and features of TiO.sub.2 and AgNPs were studied using SEM (Inspect S50) and TEM (Morgagni 268). For TEM analysis, samples were prepared by dispersing in ethanol followed by shaking in an ultrasonicator for 20 min, and then a suspended drop was dried at room temperature on the carbon-coated copper grid; see S. Rehman, et al., Isolation and characterization of a novel thermophile; Bacillus haynesii, applied for the green synthesis of ZnO nanoparticles, A
[0198] Antibacterial activity of biosynthesized NPs. Antibacterial activities of synthesized, TiO.sub.2NPs and AgNPs were studied against the human pathogenic Gram-negative bacteria and Gram positive bacteria, namely, E. coli ATCC35218 and S. aureus ATCC29213, respectively, by broth dilution method. The bacterial strains were maintained and nutrient agar media (NA).
[0199] In preparation for the study, a homogeneous suspension of NPs was prepared by sonication for 15-20 min at 30° C., ranging in the concentration from 250 to 15.62 mg mL.sup.−1. Mueller-Hinton (MHB) was used to grow test organisms for overnight at 37° C. and subsequently adjusted to the cell frequency of 10.sup.6 CFUmL.sup.−1.
[0200] The adjusted inoculum of each bacterial strain was added to the solution of MHB with NPs and incubated with shaking at 37° C. for 24 h. Untreated bacteria was used as a negative control.
[0201] The MIC was recorded as the least concentration of NPs, which had no growth visible in the broth(absence of turbidity). Following the MIC evaluation, MBC was obtained by taking an aliquot of the MIC for further plating on the MHA plates. The inoculated plates were further incubated for overnight at 37° C. and the MBC was taken as the concentration at which no growth or CFU less than 3 was obtained; see S. Akhtar, et al., Synthesis of M11.sub.0.5 Zn.sub.0.5 Sm.sub.xEu.sub.xF.sub.e1.8-.sub.2xO.sub.4 Nanoparticles via the Hydrothermal Approach Induced Anti-Cancer and Anti-Bacterial Activities, N
[0202] Study of topological changes in treated bacteria. Additionally, the treated cultures of E. coli and S. aureus were studied by SEM for the morphological and physiological alteration caused by exposure to NPs. Precisely, adjusted bacterial cells were treated at the concentration obtained as its MIC and subjected to incubation at 37° C. for overnight. Untreated samples were included as the negative control. Later treated and untreated cells were centrifuged at 12 000 rpm for 10 min. The harvested cells were thrice washed using PBS and primarily fixed using 2.5% glutaraldehyde for 4 h, then again fixed with 1% osmium tetroxide for 1-2 h. Cells were washed multiple times and further dehydrated by varying conc. of ethanol (50%, 70%, 90%,100%). The cells were placed on aluminum stubs and dried using desecrator. Finally, gold coating was done and cells were examined by SEM at an accelerating voltage of 20 kV; see Akhtar, et al., supra, incorporated by reference.
[0203] Antiproliferative activity:. Cell culture & treatments. Human colorectal carcinoma cells (HCT-116) were used for the study. DMEM medium was used for cell culture which was supplemented with 10% fetal bovine serum(FBS); (10%) L-glutamine; 10% selenium chloride; 120 mg mL.sup.−1 and streptomycin; and 120 units per mL penicillin in 5% CO.sub.2 incubator (Thermo Scientific Heracell-150) at temperature 37° C. The cells with more than 70-80% confluence were used for the TiO.sub.2 and AgNPs treatments.
[0204] The treatments of HCT-116 cells were carried out with different concentrations of nanoparticles ranging from 0.5 to 8.0 mg mL.sup.−1. The cells were observed after the time span of 48 h. Experiments were carried out in triplicate for statistical analysis; see F. Khan, et al., FMSP-nanoparticles induced cell death on human breast adenocarcinoma cell line (MCF-7 cells): morphometric analysis, B
[0205] Cancer cell morphology. The cell morphology of untreated and treated HCT-116 cells was examined post 48 h under inverted microscope (TS100E-Eclipse, Nikon) and compared the under 200× magnifications.
[0206] Cytotoxicity by MTT assay. The cells with confluency of 70-80% in 96-well cell culture plates were subjected to MTT assay. After 48 h, MTT (5 mg mL_1) was added in all the wells and kept for 4 h. Later, DMSO was added and plate was read in an ELISA Plate Reader 570 nm wavelength (Biotek Instruments, USA). 20 The (%) percentage of cell viability was calculated as per given formula:
[0207] % cell viability=(optical density of nanoparticles)/(optical density of controls) X 100.
[0208] Nuclear staining by DAPI. The cells were stained with DAPI staining to study the effects of exposure to TiO.sub.2NPs and AgNPs on the cell nucleus. After 48 h, the treated and untreated HCT-116 cells were immersed in an ice-cold (4%) paraformaldehyde. Later, the cells were added with Triton X-100 prepared in PBS for5 min to premetallize the cell membrane. The cells were stained using DAPI (5 mg mL.sup.−1) in PBS, prepared in dark. Washing with Triton X-100 was done, followed by examining the nuclear morphology under confocal scanning microscope (Zeiss, Germany) equipped with digital camera; see F. Khan, et al., FMSP-nanoparticles induced CELL DEATH ON HUMAN BREAST ADENOCARCINOMA CELL LINE (MCF-7 CELLS): MORPHOMETRIC ANALYSIS, B
[0209] In the present study, cell viability data were presented as mean (±) standard deviation (SD) which were obtained from three independent experimental repeats. One-way ANOVA followed by Dunnett's post hoc test with GraphPad Prism software GraphPad Software, Inc., La Jolla, Calif., USA) for the statistical analysis. P<0.05 was considered to indicate a statistically significant difference.
TABLE-US-00002 TABLE 2 Gene bank accession numbers and top BLAST match sequences of the mushroom isolated along with maximum identity, query coverage. BLAST Match Sequence Accession Maximum Number Reference Accession Number Coverage identity MK635350 MH860248.1 Fomitopsis pinicola 100% 100% KC422604.1 Boletus reticulatus 99% 98.75% DQ131609.1 Boletus aestivalis 99% 98.75% DQ990837.1 Uncultured mycorrhiza 98% 98.99% KY595992.1 Boletus reticulatus 91% 99.18% AY680963.1 Boletus aestivalis 89% 98.88% KC261839.1 Boletus reticulatus 71% 99.47%
[0210] The term Fomitopsis pinicola as used herein describes the strain deposited under MK635350 as well as phenotypically related strains, such as those described in Table 2 or those having a maximum identity of at least 98.5, 90.6, 98.7, 98.8, 98.9%, preferably at least 99.0, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9 or 100%, or a maximum coverage of at least 98, 99 or 100%.
[0211] Phenotypic and genotypic studies of F. pinicola. The phenotypic analysis of mushroom namely F. pinicola was done. Spores are 5.5-7 x 4.0-5.0 μtm, oval, smooth: spore print pale yellow. Spores are bilaterally symmetrical. The shape of the hilar appendix is beaked (
[0212] Characterization of biosynthesized TiO.sub.2 and AgNPs. The production of F. pinicola TiO.sub.2and AgNPs was indicated by examining the color change in the reaction mixture.
[0213] In the case of TiO.sub.2 NP synthesis using F. pinicola a reduced crystallinity and broadness of peaks indicates nanosized TiO.sub.2 formation with major phase of rutile, see
[0214] In the case of AgNP synthesis using F. pinicola the XRD spectra of AgNPs showed clear diffraction lines corresponding to (111), (200) and (220) planes indicating the presence of AgNPs; see
[0215] The presence of unidentified peak at about 57.5° could be attributed to the crystalline components present in the extract. While not being bound to a particular theory or explanation, the presence of active ingredients like polyphenols and flavonoids in the F. pinicola extract may play a role as bioreductant in reducing metal ions of metal source to nanoparticles.
[0216]
[0217] In the case of AgNPs, presence of difference functional groups corresponding to N—H, O—H, and methylene C—H was observed between 1000-3700 cm.sup.−1 (
[0218] The functional group analysis using FT-IR suggest that active components (amino, hydroxyl and methyl) in F. pinicola act as bioreductants to produce TiO.sub.2 and AgNPs.
[0219] The coordination sites of TiO.sub.2 and AgNPs prepared using F. pinicola were studied using diffuse reflectance UV-visible spectroscopy.
[0220] In case of TiO.sub.2 NPs, isolated tetrahedral TO.sup.+ species was observed with a band at about 220 nm (
[0221] In case of AgNPs, the sample exhibited presence of three kinds of Ag species indicating the variation in coordination environments (
[0222]
[0223] For TiO.sub.2 NPs, surface features and distribution have been examined through SEM (
[0224] For AgNPs, on the other hand, SEM micrographs (
[0225] Antibacterial activity of synthesized NPs. Assays were performed by examining the MIC and MBC values of F. pinicola nanoparticles against E. coli and S. aureus. See
[0226] On treatment with TiO.sub.2 NPs, the MIC/MBC values were 62.5/125 and 62.5/125 mg mL.sup.−1 for E. coli and S. aureus, respectively (
[0227] Whereas upon treatment with AgNPs, the MIC/MBC values obtained were 15.62/62.5 and 62.5/125 mgmL.sup.−1 for E. coli and S. aureus, respectively (
[0228] Study of topological changes in treated bacteria. Morphological changes to the tested bacteria induced by synthesized TiO.sub.2 and AgNPs were further studied by SEM.
[0229] The control (untreated) E. coli cells, appeared as normal rod-shaped cells with a consistent and smooth cell surface (
[0230] The treatment of E. coli cells with TiO.sub.2NPs produced some structural alterations (
[0231] Although treated E. coli with both the NPs was not found intact, with irregularities at cell surfaces seen.
[0232] Treatment of E. coli with AgNPs severely affected morphology (
[0233] Untreated S. aureus control cells are shown by
[0234] On the contrary to the control cells, the treated S. aureus cells exhibited irregularities and distorted cell surfaces. Both the TiO.sub.2 and AgNPs had similar effects on the Gram-positive bacteria.
[0235] Antiproliferative activity. The dose-depended effects of F. pinicola nanoparticles on cancer cells were evaluated.
[0236] TiO.sub.2NPs showed strong cytotoxic effects on cancer cell viability as a majority of the cancer cells were found dead after treatments of lower 0.5 mg mL.sup.−1 (
[0237] TiO.sub.2NP treated cells showed significant alteration in structure and the cell nucleus as revealed by light and confocal microscopy (
[0238] Treatment with AgNPs also produced strong cytotoxic effects on cancer cell viability as a majority of the cells were found dead after the treatment of 0.5 mg mL.sup.−1 (
[0239] As shown in this example, TiO.sub.2NPs and AgNPs containing Fomitopsis pinicola exhibited antibacterial activity against both Gram-negative and Gram-positive bacteria and inhibited the growth of, or killed, cancer cells. These antimicrobial and anti-cancer properties may be applied for treatment of bacterial infections or cancer as well as in industries, such as food production and distribution, or cosmetics.